D. Singh (Manchester, United Kingdom), A. Sinha (Amsterdam, Netherlands)
Intravenous (IV) reslizumab improves asthma control, symptoms, and quality of life in patients with historically elevated blood eosinophils
P. Chanez (Marseille, France), Y. Adir (Haifa, Israel), M. Castro (St Louis, United States of America), L. Pahus (Marseille, France), M. Mcdonald (Malvern, United States of America), L. Hickey (Malvern, United States of America), M. Garin (Malvern, United States of America)
|    |
Oral glucocorticoid-sparing effects of mepolizumab. A real-life study.
A. Bjerrum (Aarhus, Denmark), J. Schmid (Aarhus, Denmark), T. Skjold (Aarhus, Denmark)
| |
Oral corticosteroid (OCS)-sparing effect of tralokinumab in severe, uncontrolled asthma: the TROPOS study
W. Busse (Madison, United States of America), G. Brusselle (Ghent, Belgium), S. Korn (Mainz, Germany), P. Kuna (Lodz, Poland), A. Magnan (Nantes, France), D. Cohen (Gaithersburg, United States of America), K. Bowen (Gaithersburg, United States of America), T. Piechowiak (Mississauga, Canada), M. Wang (Cambridge, United Kingdom), G. Colice (Gaithersburg, United States of America)
| |
Benralizumab efficacy in patients with uncontrolled eosinophilic asthma by age at diagnosis
S. Wenzel (Pittsburgh, PA, United States of America), G. Brusselle (Ghent, Belgium), I. Hirsch (Gaithersburg, MD, United States of America), J. Zangrilli (Gaithersburg, MD, United States of America), S. Rastogi (Gaithersburg, MD, United States of America)
| |
Serum GAL3 predict response in omalizumab-treated patients with severe allergic asthma: the PROXIMA study
A. Riccio (Genoa, Italy), P. Mauri (Segrate, Italy), M. Bartezaghi (Origgio, Italy), F. Saccheri (Origgio, Italy), G. Canonica (Milan, Italy)
| |
Bronchial thermoplasty in severe asthmatics : a retrospective study on 10 cases with one year follow-up
A. Frix (Liege, Belgium), V. Heinen (Liege, Belgium), F. Schleich (Liege, Belgium), B. Duysinx (Liege, Belgium), V. Paulus (Liege, Belgium), R. Louis (Liege, Belgium)
| |
Further resolution of non-T2 asthma subtypes from high-throughput sputum transciptomics data in U-BIOPRED
N. Zounemat Kermani (London, United Kingdom), S. Pavlidis (London, United Kingdom), M. Saqi (London, United Kingdom), Y. Guo (London, United Kingdom), P. Agapow (London, United Kingdom), C. Kuo (London, United Kingdom), M. Loza (Springhouse, United States of America), F. Baribaud (Springhouse, United States of America), A. Rowe (Springhouse, United States of America), A. Sousa (Stockley Park, United Kingdom), B. De Meulder (Lyon, France), D. Lefaudeux (Lyon, France), L. Fleming (London, United Kingdom), J. Corfield (Nottingham, United Kingdom), R. Knowles (Stevenage, United Kingdom), C. Auffray (Lyon, France), R. Djukanovic (Southampton, United Kingdom), P. Sterk (Amsterdam, Netherlands), I. Adcock (London, United Kingdom), F. Chung (London, United Kingdom)
| |
Extrafine glycopyrronium bromide (GB) in addition to extrafine beclomethasone dipropionate/formoterol fumarate (BDP/FF) in uncontrolled asthmatic patients
D. Singh (Manchester, United Kingdom), G. Georges (Cary , United States of America), M. Scuri (Parma, Italy), I. Valente (Parma, Italy), A. Guasconi (Parma, Italy), F. Zuccaro (Parma, Italy), A. Papi (Ferrara, Italy)
| |
Safety profile of tiotropium add-on therapy in paediatric patients by gender
C. Vogelberg (Dresden, Germany), E. Hamelmann (Bielefeld, Germany), M. Engel (Ingelheim am Rhein, Germany), G. El Azzi (Ingelheim am Rhein, Germany), S. Vulcu (Ingelheim am Rhein, Germany), S. Szefler (Aurora, United States of America)
| |
Methodology of clinical trials in COPD exacerbations: Eligibility criteria and endpoint selection.
A. Mathioudakis (Manchester, United Kingdom), M. Moberg (Hvidovre, Denmark), J. Janner (Hvidovre, Denmark), P. Alonso-Coello (Barcelona, Spain), J. Vestbo (Manchester, United Kingdom)
| |
Patients’ ability to use a novel fluticasone propionate/formoterol breath-triggered inhaler (BTI) vs. budesonide/formoterol dry powder inhaler (DPI)
D. Bell (Belfast , United Kingdom), W. Timmer (Gauting, Germany), L. Mansfield (Cambridge, United Kingdom), M. Lomax (Cambridge, United Kingdom), B. Grothe (Cambridge, United Kingdom), T. Overend (Cambridge, United Kingdom)
| |
Dual bronchodilation vs triple therapy in the real-life DACCORD study
C. Criee (Bovenden, Germany), P. Kardos (Frankfurt, Germany), H. Worth (Fuerth, Germany), N. Lossi (Nuernberg, Germany), K. Kostikas (Basel , Switzerland), C. Vogelmeier (Marburg, Germany), R. Buhl (Mainz, Germany)
| |
Lung deflation with indacaterol/glycopyrronium improves pulmonary microvascular blood flow in the CLAIM Study
J. Vogel-Claussen (Hannover, Germany), C. Schoenfeld (Hannover, Germany), C. Czerner (Hannover, Germany), J. Renne (Hannover, Germany), T. Kaireit (Hannover, Germany), H. Tillmann (Basel, Switzerland), K. Berschneider (Nuremberg, Germany), S. Hiltl (Nuremberg, Germany), J. Bauersach (Hannover, Germany), T. Welte (Hannover, Germany), J. Hohlfeld (Hannover, Germany)
| |
Disease control and treatment pathways of asthma patients after initiating ICS/LABA
R. Buhl (Mainz, Germany), L. Heaney (Belfast, United Kingdom), E. Loefroth (Täby, Sweden), P. Larbig (Basel, Switzerland), K. Kostikas (Basel, Switzerland), V. Conti (Basel, Switzerland), H. Cao (East Hanover, United States of America)
| |
Exacerbations and Eosinophil Levels in ACCESS Cohort Participants Prescribed Inhaled Triple Therapy
H. Müllerová (Uxbridge, United Kingdom), C. El-Baou (Uxbridge, United Kingdom), D. Galkin (Research Triangle Park, United States of America), P. Jones (Brentford, United Kingdom)
| |
Efficacy and safety profile of xanthines in COPD: a network meta-analysis
M. Cazzola (Rome, Italy), L. Calzetta (Rome, Italy), P. Barnes (London, United Kingdom), G. Criner (Philadelphia, United States of America), F. Martinez (New York, United States of America), A. Papi (Ferrara, Italy), M. Matera (Naples, Italy)
| |
Impact of doxofylline in COPD: a pair-wise meta-analysis
M. Cazzola (Rome, Italy), L. Calzetta (Rome, Italy), P. Rogliani (Rome, Italy), C. Page (London, United Kingdom), M. Matera (Naples, Italy)
| |
A randomized, placebo controlled 4-week study in COPD of QBW251, a potentiator of the cystic fibrosis transmembrane conductance regulator (CFTR) protein
S. Rowe (Birmingham, United States of America), N. Haque (Cambridge, United States of America), S. Gleason (Cambridge, United States of America), I. Jones (Cambridge, United States of America), K. Kulmatycki (Cambridge, United States of America), D. Rowlands (Cambridge, United States of America), S. Grant (Cambridge, United States of America)
| |